Nalu Bio
Nalu Bio is a biotech company leveraging a proprietary AI-driven chemistry platform to develop prescription and nonprescription cannabinoid-based Vitamins, Minerals, and Supplements (VMS) products targeting the endocannabinoid system (ECS). Their innovative approach produces chemistry-derived cannabinoids that are molecularly identical to plant cannabinoids but offer improved cost-efficiency, scalability, quality, and consistency. The company focuses on addressing major global health challenges such as chronic pain, weight management, stress, and sleep disorders with non-addictive pain therapeutics and wellness supplements. Nalu Bio has built a robust IP portfolio including method-of-use patents and new chemical entities, and has scaled production through global manufacturing partnerships. Their business model includes licensing and product commercialization, aiming to replace opioids with safer alternatives and create a new category in health and wellness.
Nalu Bio
Nalu Bio is a biotech company leveraging a proprietary AI-driven chemistry platform to develop prescription and nonprescription cannabinoid-based Vitamins, Minerals, and Supplements (VMS) products targeting the endocannabinoid system (ECS). Their innovative approach produces chemistry-derived cannabinoids that are molecularly identical to plant cannabinoids but offer improved cost-efficiency, scalability, quality, and consistency. The company focuses on addressing major global health challenges such as chronic pain, weight management, stress, and sleep disorders with non-addictive pain therapeutics and wellness supplements. Nalu Bio has built a robust IP portfolio including method-of-use patents and new chemical entities, and has scaled production through global manufacturing partnerships. Their business model includes licensing and product commercialization, aiming to replace opioids with safer alternatives and create a new category in health and wellness.
TL;DR
Founded: 2019
Headquarters: San Francisco, California
Focus: AI-driven, chemistry-first therapeutics targeting the endocannabinoid system (ECS)
Industry: Biotechnology
Known funding (total reported): USD 13,750,000
Flybridge, Golden Seeds, Sacramento Angels, Bonaventure Equity, Springboard Enterprises